370 related articles for article (PubMed ID: 31317798)
1. Pembrolizumab for the treatment of head and neck squamous cell cancer.
Ho WJ; Mehra R
Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
[No Abstract] [Full Text] [Related]
2. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
5. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
7. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N
Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706
[TBL] [Abstract][Full Text] [Related]
8. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
Nan X; Gold KA; Cohen E
Oncology (Williston Park); 2018 Dec; 32(12):617-9, 625-6. PubMed ID: 30632130
[TBL] [Abstract][Full Text] [Related]
10. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
11. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
12. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Emancipator K; Huang L; Aurora-Garg D; Bal T; Cohen EEW; Harrington K; Soulières D; Le Tourneau C; Licitra L; Burtness B; Swaby R
Mod Pathol; 2021 Mar; 34(3):532-541. PubMed ID: 33239737
[TBL] [Abstract][Full Text] [Related]
13. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Italiano A; Cassier PA; Lin CC; Alanko T; Peltola KJ; Gazzah A; Shiah HS; Calvo E; Cervantes A; Roda D; Tosi D; Gao B; Millward M; Warburton L; Tanner M; Englert S; Lambert S; Parikh A; Afar DE; Vosganian G; Moreno V
Cancer Immunol Immunother; 2022 Feb; 71(2):417-431. PubMed ID: 34216247
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
16. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
17. Exceptional Response to PD-1 Blockade as First-Line Therapy in Head and Neck Squamous Cell Carcinoma.
Kumai T; Komatsuda H; Minami Y; Harabuchi Y
ORL J Otorhinolaryngol Relat Spec; 2020; 82(6):343-350. PubMed ID: 32882699
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]